Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arrowhead Pharmaceuticals (ARWR) stocks in Canada

Learn how to easily invest in Arrowhead Pharmaceuticals stocks.

Arrowhead Pharmaceuticals (ARWR) is a leading biotechnology business based in the US. It opened the day at $65.81 after a previous close of $65.32. During the day the price has varied from a low of $64.78 to a high of $67.4402. The latest price was $67.14 (25 minute delay). Arrowhead Pharmaceuticals is listed on the NASDAQ and employs 329 staff. All prices are listed in US Dollars.

How to buy shares in Arrowhead Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARWR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arrowhead Pharmaceuticals stock price (NASDAQ:ARWR)

Use our graph to track the performance of ARWR stocks over time.

Arrowhead Pharmaceuticals shares at a glance

Information last updated 2021-07-09.
Previous close$65.32
Change $1.82
Change % 2.7863%
Volume 792,958
Information last updated 2022-01-17.
52-week range$55.28 - $93.66
50-day moving average $68.77
200-day moving average $68.87
Wall St. target price$88.17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.36

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Arrowhead Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Arrowhead Pharmaceuticals price performance over time

Historical closes compared with the close of $67.14 from 2022-01-19

1 week (2022-01-13) 16.60%
1 month (2021-12-20) -4.81%
3 months (2021-10-18) 1.51%
6 months (2021-07-20) -1.13%
1 year (2021-01-20) -19.53%
2 years (2020-01-17) 19.00%
3 years (2019-01-18) 362.40%
5 years (2017-01-20) 3,589.01%

Is Arrowhead Pharmaceuticals under- or over-valued?

Valuing Arrowhead Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arrowhead Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Arrowhead Pharmaceuticals's EBITDA

Arrowhead Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.9 million.

The EBITDA is a measure of a Arrowhead Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Arrowhead Pharmaceuticals financials

Revenue TTM $138.3 million
Gross profit TTM $138.3 million
Return on assets TTM -15.11%
Return on equity TTM -32.36%
Profit margin -101.85%
Book value $3.92
Market capitalisation $6 billion

TTM: trailing 12 months

Arrowhead Pharmaceuticals share dividends

We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.

Have Arrowhead Pharmaceuticals's shares ever split?

Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 17 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.

Arrowhead Pharmaceuticals share price volatility

Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $55.278 up to $93.66. A popular way to gauge a stock's volatility is its "beta".

ARWR.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 1.2255. This would suggest that Arrowhead Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.

Stocks similar to Arrowhead Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site